VRDN · Viridian Therapeutics, Inc.

The thesis

Viridian Therapeutics has a modestly better-than-even case to beat the S&P 500 over three months because its first drug, Lumvoa, opened ahead of estimates and $955.2 million in cash funds the launch. Fourth-quarter Lumvoa sales and the elegrobart filing planned for the first quarter of 2027 settle it.

The Food and Drug Administration (FDA) approved Lumvoa (veligrotug), an intravenous antibody for thyroid eye disease, in June 2026, according to the company's 10-Q. Net product revenue reached $24.7 million in the third quarter, its first full quarter on sale, with more than 100 patients on therapy at 30 September. GuruFocus cited a $19.16 million estimate. Chief executive Steve Mahoney said the launch "has exceeded expectations."

The narrative is accelerating: attention has moved from approval to sales since the 4 November 2026 report, and eight brokers raised their price targets on 4 November 2026 and 5 November 2026. The shares trade as an emerging commercial company, moving on each new sales and pipeline disclosure.

Bullish and bearish views on Viridian Therapeutics, Inc.

The bull case on Viridian Therapeutics, Inc. (VRDN), in brief: First quarter beat the cited estimate. The bear case: Commercial costs have climbed quickly.

Bull case

• First quarter beat the cited estimate. Lumvoa net product revenue was $24.7 million in the quarter ended 30 September 2026, against the $19.16 million estimate cited by GuruFocus. Benzinga reported the $0.81 per-share loss against a $1.00 estimate.
• The incumbent shows the market's size. Amgen's Tepezza, approved in 2020, sold $576 million worldwide in the second quarter of 2026, up 14% year over year. Amgen's third-quarter Tepezza figure was not available for this note, so share gain and market growth cannot yet be separated.
• A billing code arrives in January. The Centers for Medicare & Medicaid Services assigned Lumvoa permanent code J3242, effective 1 January 2027. Permanent codes tend to simplify reimbursement for infused drugs, a view that first-half 2027 sales will test.
• An at-home follow-on is close to filing. Viridian expects to submit its Biologics License Application for elegrobart in the first quarter of 2027, following positive REVEAL-1 and REVEAL-2 phase 3 results. The company plans an autoinjector dosed every four or eight weeks, sold through the Lumvoa commercial team.
• The company says this cash, plus expected product revenue, funds current plans "through profitability."

Bear case

• Commercial costs have climbed quickly. Selling, general and administrative expense rose to $57.6 million in the third quarter of 2026 from $24.3 million a year earlier. The net loss was $101.2 million, more than four times Lumvoa's revenue in the quarter.
• Amgen is building its own injection. Amgen's subcutaneous Tepezza showed a 76.7% proptosis (eye-bulging) response rate at 24 weeks, reported in April 2026. Elegrobart's convenience edge shrinks if Amgen's version reaches the market first.
• Early sales can flatter a launch. First-quarter revenue may include initial purchases by distributors and infusion sites. Fourth-quarter revenue that lags patient growth would show this effect.
• Its agreement with DRI takes a tiered royalty starting at 7.5% of annual US net sales up to $600 million.
• Recent gains look stretched. The 14-day relative strength index was 88.5 on 5 November 2026, above the 70 commonly read as overbought. Shares fell that day despite the target raises.

Price setup

The last close was $28.55 on 5 November 2026, from adjusted daily closes. That sits 15.5% below the 52-week high of $33.78, after a 23.8% rise over three months. MarketBeat showed the shares at $28.94 at midday on 5 November 2026, down $0.12, before the lower close.

Broker targets after the report run from Evercore ISI's $33 to Leerink Partners' $54. In between are Wells Fargo at $34, Needham at $38, HC Wainwright at $40, RBC at $41, and Wedbush and Truist at $42. MarketBeat puts the average at $39.55, with ten Buy ratings and one Sell.

Crowding evidence is mixed. The overbought reading is the clearest sign. MarketBeat reported that insider Jennifer Tousignant sold 14,212 shares on 19 August 2026 at an average of $24.50, for $348,194. The 10-Q shows no at-the-market share sales in the first nine months of 2026, and the May offering came before approval. The next earnings date has not been announced.

Catalysts, next 30 days

• 16 November 2026: Jefferies Global Healthcare Conference fireside chat in London, the first scheduled management appearance after the report.
• 17 November 2026: UBS Global Biopharma London Conference fireside chat.
• ~31 December 2026, est.: Phase 1 healthy-volunteer results for VRDN-008, an antibody-type drug targeting the neonatal Fc receptor, plus development plans for that program. The company guides to the fourth quarter without a date, so this may fall beyond 30 days.
• ~31 December 2026, est.: Start of the phase 1 patient trial of VRDN-292 in Graves' disease, also guided to the fourth quarter.
• 1 January 2027: Permanent billing code J3242 takes effect.
• ~31 March 2027, est.: Elegrobart application to the FDA, guided to the first quarter of 2027.
• Date not announced: Fourth-quarter report, the first test of whether Lumvoa sales keep growing.

What would change the view

The case breaks if fourth-quarter Lumvoa net revenue comes in below the third quarter's $24.7 million. A second break would be elegrobart's filing slipping past the first quarter of 2027, or an FDA request for more trial work. Amgen winning approval for subcutaneous Tepezza before elegrobart is filed would weaken the at-home argument without ending the Lumvoa case.

On price, a daily close below $24.50 ends the thesis. That level is the average price of the 19 August 2026 insider sale, and a close under it would give back the rise since that date. A close above the 52-week high of $33.78, paired with fourth-quarter revenue growth, would strengthen the case.

What it trades with

The read rests on Lumvoa sales rather than on the group. Amgen's Tepezza figures are the most direct cross-check, since falling Tepezza sales alongside rising Lumvoa sales would point to share gain.

FrontierPicks tracks Viridian with DTIL and COAG in its rare-disease and gene-therapy group. Attention on that group was maturing on 31 July 2026 and 7 August 2026 and accelerating again on 6 November 2026. A group-wide decline with Lumvoa sales intact would not break the case unless the shares also closed below $24.50.